Success Metrics

Clinical Success Rate
100.0%

Based on 7 completed trials

Completion Rate
100%(7/7)
Active Trials
1(13%)
Results Posted
43%(3 trials)

Phase Distribution

Ph phase_1
2
25%
Ph phase_3
4
50%

Phase Distribution

2

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 3Large-scale testing
4(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

7 of 7 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Completed(7)

Detailed Status

Completed7
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (33.3%)
Phase 34 (66.7%)

Trials by Status

completed788%
recruiting113%

Recent Activity

1 active trials
Showing 5 of 8
recruitingphase_1

Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission

NCT02140255
completed

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

NCT04518228
completedphase_1

Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin

NCT01571414
completedphase_3

HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children

NCT00978068
completedphase_3

Treatment Options for Protease Inhibitor-exposed Children

NCT01146873
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT02140255Phase 1

Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission

Recruiting
NCT04518228

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

Completed
NCT01571414Phase 1

Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin

Completed
NCT00978068Phase 3

HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children

Completed
NCT01146873Phase 3

Treatment Options for Protease Inhibitor-exposed Children

Completed
NCT00977756

IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults

Completed
NCT00640263Phase 3

Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding

Completed
NCT00711009Phase 3

Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8